Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Crystal L Mackall

Showing results (181-190 of 232) with videos related to

Pageof 24
Sort By:
Science (New York, N.Y.)|April 2, 2021
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodelingEvan W Weber, Kevin R Parker, Elena Sotillo, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Cancer Cell|January 26, 2024
Inosine induces stemness features in CAR-T cells and enhances potencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Research Square|November 21, 2023
FOXO1 is a master regulator of CAR T memory programmingAlexander Doan, Katherine P Mueller, Andy Chen, et al.
Cancer Research|December 2, 2024
Tumor-Associated Microglia Secrete Extracellular ATP to Support Glioblastoma ProgressionCaren Yu-Ju Wu, Yiyun Chen, Ya-Jui Lin, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Inosine Induces Stemness Features in CAR T cells and Enhances PotencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Blood Cancer Journal|April 4, 2026
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapyMasooma Shifa Rana, Sebastian Fernandez-Pol, Alexandria Jensen, et al.
Eclinicalmedicine|November 13, 2023
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patternsValentin Barsan, Yimei Li, Snehit Prabhu, et al.
Cancer Discovery|January 8, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCLYi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, et al.
Pageof 24

Showing results (181-190 of 232) with videos related to

Sort By:
Pageof 24
Science (New York, N.Y.)|April 2, 2021
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodelingEvan W Weber, Kevin R Parker, Elena Sotillo, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Cancer Cell|January 26, 2024
Inosine induces stemness features in CAR-T cells and enhances potencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Research Square|November 21, 2023
FOXO1 is a master regulator of CAR T memory programmingAlexander Doan, Katherine P Mueller, Andy Chen, et al.
Cancer Research|December 2, 2024
Tumor-Associated Microglia Secrete Extracellular ATP to Support Glioblastoma ProgressionCaren Yu-Ju Wu, Yiyun Chen, Ya-Jui Lin, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Inosine Induces Stemness Features in CAR T cells and Enhances PotencyDorota D Klysz, Carley Fowler, Meena Malipatlolla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Blood Cancer Journal|April 4, 2026
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapyMasooma Shifa Rana, Sebastian Fernandez-Pol, Alexandria Jensen, et al.
Eclinicalmedicine|November 13, 2023
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patternsValentin Barsan, Yimei Li, Snehit Prabhu, et al.
Cancer Discovery|January 8, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCLYi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, et al.
Pageof 24